Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Antiviral activity against West Nile virus Kern 515 infected in African green monkey Vero 76 cells
Assay data:1 Tested
SummaryPubMed Citation
Antiviral activity against West Nile virus 13-104 infected in african green monkey Vero cells
Antiviral activity against West Nile virus Eg101 infected in african green monkey Vero cells
Antiviral activity against WNV infected in human Huh-7 cells preincubated with cells for 1 hr and measured after 4 days by plaque reduction assay
Assay data:3 Active, 2 Activity ≤ 1 µM, 4 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed Citation
Antiviral activity against West Nile virus infected in human Huh7.5 cells assessed as log reduction in plaque forming units at 1 mM cells were pretreated with compound for 24 hrs followed by drug removal and subsequent viral infection for 1 hr and later incubated with compound and measured at 3 days post-infection
Antiviral activity against West Nile virus infected in human Huh-7 cells assessed as log reduction in plaque forming units at 1 mM cells were pretreated with compound for 24 hrs followed by drug removal and subsequent viral infection for 1 hr and later incubated with compound and measured at 3 days post-infection
Antiviral activity against West Nile virus infected in human Huh7.5 cells assessed as reduction in virus-induced cytopathic effect at 0.1 to 1 mM cells were pretreated with compound for 24 hrs followed by drug removal and subsequent viral infection for 1 hr and later incubated with compound and measured at 3 days post-infection
Antiviral activity against West Nile virus infected in African green monkey Vero cells assessed as reduction in virus-induced cytopathic effect at 0.1 to 1 mM cells were pretreated with compound for 24 hrs followed by drug removal and subsequent viral infection for 1 hr and later incubated with compound and measured at 3 days post-infection
Assay data:2 Tested
Antiviral activity against West Nile virus infected in human Huh-7 cells assessed as reduction in virus-induced cytopathic effect at 0.1 to 1 mM cells were pretreated with compound for 24 hrs followed by drug removal and subsequent viral infection for 1 hr and later incubated with compound and measured at 3 days post-infection
Antiviral activity against West Nile virus New York 99 infected in golden hamster BHK-21 cells co-expressing renilla luciferase assessed as inhibition of viral DNA replication incubated for 24 hrs
Inhibition of 6his tagged West Nile virus NS2B-NS3 protease expressed in Escherichia coli BL21 CodonPlus (DE3)-RIPL cells using Pyr-RTKR-AMC as substrate assessed as substrate cleavage preincubated for 30 mins followed by substrate addition by fluorescence spectrophotometric analysis
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Antiviral activity against West Nile virus NY99 infected in human A549 cells measured after 48 hrs by plaque reduction assay
Antiviral activity against West Nile virus infected in human A549 cells measured after 42 hrs by plaque reduction assay
Antiviral activity against West Nile virus NY003356V2 infected in human A549 cells measured after 48 hrs by plaque reduction assay
Assay data:1 Active, 1 Tested
SummaryCompounds, ActivePubMed Citation
Inhibition of West Nile virus NS2B-NS3 protease expressed in Escherichia coli BL21 (DE3) cells using Bz-Nle-K-K-R-AM as substrate preincubated for 10 mins followed by substrate addition and measured after 60 mins by fluorescence based assay
SummaryPubMed CitationRelated BioAssays by Target
Inhibition of recombinant West Nile virus NS2B-NS3 protease using Pyr-RTKR-AMC as substrate assessed as change in fluorescence intensity preincubated for 15 mins followed by substrate addition by fluorescence based microplate reader analysis
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Uncompetitive inhibition of recombinant West Nile virus NS2B-NS3 protease using Pyr-RTKR-AMC as substrate assessed as inhibition constant preincubated for 15 mins followed by substrate addition
Assay data:2 Active, 2 Tested
Inhibition of West Nile virus NS2B (49 to 96 residues)-NS3 (2 to 184 residues) protease expressed in Escherichia coli BL21-rosetta cells using Bz-Nle-Lys-Lys-Arg-AMC as substrate preincubated for 10 mins followed by substrate addition and measured every 30 secs
Inhibition of recombinant West Nile virus NS2B-NS3 protease using pERTKR-AMC as substrate assessed as inhibition constant by fluorescence based assay
Inhibition of West Nile virus NS2B-NS3 protease using Boc-Gly-Lys-Arg-7-amino-4-methyl coumarin as substrate preincubated for 15 mins followed by substrate addition and measured after 15 mins by fluorescence based assay
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on